Opening book details…
Can I read Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting on EtoBox?
Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting by Nicholas J. Vogelzang; Alisha M. Monnette; Yunfei Wang; Yin Wan; Yiqiong Xie; Nicholas J. Robert; Nizar M. Tannir is a Medicine article available to read on EtoBox.
What is Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting about?
## Introduction: Few studies have evaluated real-world effectiveness of lenvatinib (len)/everolimus (eve) for advanced/metastatic renal cell carcinoma (a/mrcc). this study evaluated patient profiles and clinical outcomes of second- and subsequent-line (≥ 2l) len/eve for a/mrcc. ## Patients and methods: A longitudinal retrospective study examined adult patients initiating ≥ 2l len/eve for a/mrcc from may 13, 2016, to july 31, 2019. len/eve clinical trial participants or those treated for other primary tumors were excluded. outcomes included objective response rate, duration of response, progression-free survival (pfs), time to treatment discontinuation, and overall survival. time-to-event outcomes were estimated using kaplan-meier methods. ## Results: Seventy-nine patients were assessed: the median age was 64.8 years, 78.5% were caucasian, 73.4% were male, 78.5% had an eastern cooperative oncology group performance status score of 0/1, 29.1% received 2l/3l len/eve, and the median number of prior lines of therapy was 3 (range, 1-8). at initial diagnosis, 55.7% had stage iv disease, 65.8% had international metastatic risk scores of intermediate/poor, 19.0% favorable, and 15.2% with mi
Who reads Real-world Clinical Effectiveness of Lenvatinib/Everolimus in a Heavily Pretreated Advanced/Metastatic Renal Cell Carcinoma Population in the US Community Oncology Setting?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Nicholas J. Vogelzang; Alisha M. Monnette; Yunfei Wang; Yin Wan; Yiqiong Xie; Nicholas J. Robert; Nizar M. Tannir
- Publisher
- Elsevier BV
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)